INSTITUTIONAL PRE-DOCTORAL NRSA

癌症是一系列疾病，其控制最终需要对允许细胞以不受控制的方式开始分裂并随后侵入正常组织的事件有基本的了解。细菌和真菌机会性感染已成为免疫功能低下患者发病率和死亡率的主要原因，特别是那些接受大剂量化疗以治疗实体瘤，或延长白血病、淋巴瘤和其他癌症相关血液疾病治疗的患者。拟议的培训计划的目标将是指导博士前学生在癌症发生和发病机制的多学科方面的基础研究。主要目标是培养年轻的科学家，他们将继续他们在癌症生物学和宿主-病原体相互作用方面的职业生涯，并随后对他们感兴趣的特定研究领域产生影响。该项目的教员代表了医学院对癌症发生和发病机制感兴趣的最具竞争力的科学家，他们来自病理学、生物化学和分子生物学、生理学和分子医学、医学、微生物学和免疫学等系。教员包括M.You博士(肺癌的分子遗传学)、J.C.Willey博士(肺癌相关致癌物质)、R.Ruch博士(细胞间通讯)、J.P.Tempe博士(癌症的基因治疗)、M.Ratnam博士(癌症的新化疗方法)、L.Faber博士(孕激素、免疫抑制剂和乳腺癌)、M.Pereira博士(预防结直肠癌)、D.L.Sawicki博士(病毒复制的调控)、M.Boyle博士(纤溶酶原激活和细菌发病机制)。G.T.Cole(与机会性真菌侵袭相关的免疫调节)和D.W.Metzgar(免疫的细胞因子调节)。所有博士前学生都将通过俄亥俄州医学院现有的医学计划进入疾病分子基础或分子和细胞生物学计划集中的领域。除了课程集中的要求，这个名为癌症分子病理学(MPC)的培训项目的学生将被要求参加两门以癌症为导向的课程，并参加培训项目活动(研讨会系列、期刊俱乐部、研究会议和研究务虚会)。

Cancer is a spectrum of diseases whose control will ultimately require a basic understanding of the events that permit cells to begin to divide in an uncontrolled manner and subsequently invade normal tissue. Bacterial and fungal opportunistic infections have emerged as major causes of morbidity and mortality in immunocompromised patients, particularly those undergoing high dose chemotherapy for the treatment of solid tumors, or prolonged treatment for leukemia, lymphoma and other cancer-related hematologic disorders. The objectives of the proposed training program will be to direct predoctoral students in basic research on multi-disciplinary aspects of carcinogenesis and pathogenesis. The major goal is to train young scientists who will continue their careers in cancer biology and host-pathogen interactions, and subsequently make an impact on their specific area of research interest. The faculty participants in this program represent the medical school's most competitive scientists with interest in carcinogenesis and pathogenesis, and are drawn from the Departments of Pathology, Biochemistry and Molecular Biology, Physiology and Molecular Medicine, Medicine, and Microbiology and Immunology. The faculty participants include Drs. M. You (molecular genetics of lung cancer), J.C. Willey (carcinogens implicated in lung cancer), R. Ruch (cell-cell communication), J.P. Trempe (gene therapy of cancer), M. Ratnam (novel chemotherapeutic approaches to cancer), L. Faber (progestins, immunosuppressants and breast cancer), M. Pereira (prevention of colorectal carcinoma), D.L. Sawicki (regulation of viral replication), M. Boyle (plasminogen activation and bacterial pathogenesis. G.T. Cole (immunomodulation related to opportunistic fungal invasion), and D.W. Metzgar (cytokine regulation of immunity). All predoctoral students will matriculate through the existing Medical College of Ohio's Medical Sciences Program in either the Molecular Basis of Disease or Molecular and Cellular Biology areas of programmatic concentration. In addition to the requirements of the programmatic concentration, students in this training program, called Molecular Pathogenesis of Cancer (MPC) will be required to take 2 cancer-oriented courses and participate in training program activities (seminar series, journal club, research conferences and research retreats).